Metastatic Solid Tumor Clinical Trials in Boston, Massachusetts
9 recruitingBoston, Massachusetts
Showing 1–9 of 9 trials
Recruiting
Phase 1Phase 2
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Metastatic Solid TumorSolid Tumor, AdultUnresectable Solid Tumor+1 more
Frontier Medicines Corporation403 enrolled26 locationsNCT06244771
Recruiting
Phase 1Phase 2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ovarian CancerEndometrial CancerProstate Cancer+5 more
PMV Pharmaceuticals, Inc300 enrolled76 locationsNCT04585750
Recruiting
Phase 1
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Advanced Solid TumorMetastatic Solid TumorSolid Tumor+4 more
Ankyra Therapeutics, Inc97 enrolled5 locationsNCT06171750
Recruiting
Phase 1
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Advanced Solid TumorMetastatic Solid TumorRecurrent Solid Tumor+1 more
Eli Lilly and Company490 enrolled28 locationsNCT06238479
Recruiting
Phase 1
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Advanced Solid TumorMetastatic Solid TumorNon-small Cell Lung Cancer+1 more
Eli Lilly and Company340 enrolled33 locationsNCT06561685
Recruiting
Phase 1
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Advanced Solid TumorMetastatic Solid TumorRecurrent Solid Tumor+1 more
Eli Lilly and Company420 enrolled28 locationsNCT06465069
Recruiting
Phase 1
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Metastatic Solid TumorEsophageal Squamous Cell CarcinomaGastric Adenocarcinoma+2 more
Plexium, Inc.155 enrolled10 locationsNCT07284186
Recruiting
Phase 1
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Lung CancerAdvanced Solid TumorMetastatic Solid Tumor+2 more
Circle Pharma220 enrolled10 locationsNCT06577987
Recruiting
Phase 1
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
Metastatic Solid TumorAdvanced Unresectable Solid Tumor
TopAlliance Biosciences499 enrolled24 locationsNCT04137900